Pacific Biosciences of California PACB
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Pacific Biosciences of California (PACB) Business Model and Operations Summary
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Key Insights
Pacific Biosciences of California (PACB) Core Market Data and Business Metrics
Latest Closing Price
$1.27Market Cap
$339.59 MillionPrice-Earnings Ratio
-0.80Total Outstanding Shares
273.86 Million SharesTotal Employees
796Dividend
No dividendIPO Date
October 27, 2010SIC Description
Laboratory Analytical InstrumentsPrimary Exchange
NASDAQHeadquarters
1305 O'brien Drive, Menlo Park, CA, 94025
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Short Interest
This information is bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Average Daily Volume: The average number of shares traded per day over the specified period.
Days to Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Short Interest | Bi-Weekly Change (%) | Settlement Date | Days to Cover |
|---|---|---|---|
| 53,410,201 Shares | -13.83% | 3/14/2025 | 5.31 |
| 61,979,163 Shares | -7.06% | 2/28/2025 | 4.59 |
| 66,690,554 Shares | +10.41% | 2/14/2025 | 4.13 |
| 60,400,275 Shares | -0.23% | 1/31/2025 | 5.97 |
| 60,540,209 Shares | +6.49% | 1/15/2025 | 5.58 |
| 56,848,368 Shares | +7.15% | 12/31/2024 | 8.38 |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-125.04 Million |
| Net Cash Flow, Continuing | $-125.04 Million |
| Net Cash Flow From Operating Activities | $-206.06 Million |
| Net Cash Flow From Investing Activities | $124.00 Million |
| Net Cash Flow From Operating Activities, Continuing | $-206.06 Million |
| Net Cash Flow From Financing Activities, Continuing | $-42.99 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $-309.54 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Benefits Costs and Expenses | $463.55 Million |
| Revenues | $154.01 Million |
| Income Tax Expense/Benefit | $316,000 |
| Net Income/Loss | $-309.85 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-309.65 Million |
| Comprehensive Income/Loss | $-309.65 Million |
| Comprehensive Income/Loss Attributable To Parent | $-309.65 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Inventory | $58.76 Million |
| Other Current Assets | $436.93 Million |
| Fixed Assets | $30.50 Million |
| Wages | $11.71 Million |
| Other Non-current Assets | $344.69 Million |
| Noncurrent Assets | $764.77 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||